Holliday‑Segar Disease (Primary Hyperoxaluria)

Overview

Holliday‑Segar disease, more commonly called **primary hyperoxaluria (PH)**, is a rare, inherited metabolic disorder in which the liver overproduces oxalate, a small organic acid that combines with calcium to form calcium‑oxalate crystals. These crystals can accumulate in the kidneys, urinary tract, and other organs, leading to kidney stones, chronic kidney disease, and systemic complications.

• Types: Three genetic forms are recognized:
  • PH‑1 – deficiency of the enzyme alanine‑glyoxylate aminotransferase (AGT). It accounts for ~80 % of cases and is the most severe.
  • PH‑2 – deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR).
  • PH‑3 – deficiency of 4‑hydroxy‑2‑oxoglutarate aldolase (HOGA1).
• Who it affects: Autosomal‑recessive inheritance means both parents must carry a faulty gene. Symptoms usually appear in childhood, but milder forms may not become evident until adulthood.
• Prevalence: Estimated at 1–2 per 1 million people worldwide for PH‑1; PH‑2 and PH‑3 are even rarer (< 0.5 per million). In the United States, NIH’s Rare Diseases Registry records roughly 300 diagnosed individuals, though many remain undiagnosed.

Symptoms

Symptoms result from oxalate accumulation in the kidneys and other tissues. The clinical picture can vary widely between individuals and disease types.

Renal manifestations

• Recurrent calcium‑oxalate kidney stones: Often the first sign; stones may be multiple and form at a young age.
• Nephrocalcinosis: Diffuse calcium‑oxalate deposits within the renal parenchyma, visible on ultrasound or CT.
• Progressive kidney failure: Decreased glomerular filtration rate (GFR) leading to chronic kidney disease (CKD) and, in many patients with PH‑1, end‑stage renal disease (ESRD) before age 30.
• Hematuria and flank pain: Due to stone passage or obstruction.

Systemic manifestations (usually after renal excretion declines)

• Bone pain and fractures: Calcium‑oxalate deposits in bone (osteopathy).
• Retinal deposits: Vision changes, diplopia.
• Cardiac involvement: Oxalate cardiomyopathy presenting as heart failure or arrhythmias.
• Peripheral neuropathy: Numbness or tingling from nerve compression.
• Skin lesions: Subcutaneous oxalate crystals causing painless nodules.

General symptoms

• Fatigue, decreased appetite, and growth retardation in children.
• Frequent urinary tract infections (UTIs) due to obstructive stones.
• Vomiting or nausea during acute stone episodes.

Causes and Risk Factors

Primary hyperoxaluria is caused by pathogenic variants in genes that encode liver enzymes responsible for converting glyoxylate to less harmful substances.

Genetic causes

• PH‑1 (AGXT gene): Mutations impair AGT, leading to conversion of glyoxylate → oxalate.
• PH‑2 (GRHPR gene): Mutations reduce conversion of glyoxylate → glycolate.
• PH‑3 (HOGA1 gene): Mutations affect hydroxy‑oxoglutarate metabolism, increasing oxalate production.

Risk factors

• Family history: Having a sibling or parent with PH increases carrier probability.
• Consanguineous marriage: Higher chance of inheriting two defective alleles.
• Ethnic clusters: Certain mutations are more common in French‑Canadian, Scandinavian, and Middle‑Eastern populations.
• Underlying chronic kidney disease: Reduces oxalate clearance, worsening symptoms.

Diagnosis

Early diagnosis is essential to preserve kidney function and prevent systemic oxalosis.

Clinical suspicion

• Recurrent calcium‑oxalate stones before age 10 or a family history of early‑onset stones.
• Nephrocalcinosis on imaging without an obvious secondary cause (e.g., hyperparathyroidism).

Laboratory tests

• Urine oxalate measurement: 24‑hour urine collection; values > 45 mg/24 h suggest PH (normal < 40 mg).
• Plasma oxalate: Elevated (> 30 µmol/L) in advanced disease; > 80 µmol/L often indicates systemic oxalosis.
• Kidney function panel: Serum creatinine, eGFR, electrolytes.
• Genetic testing: Targeted sequencing of AGXT, GRHPR, and HOGA1 confirms the diagnosis and guides therapy. Recommended by the American College of Medical Genetics (ACMG) for all suspected cases.

Imaging

• Ultrasound: Detects nephrocalcinosis and stones.
• Non‑contrast CT: Gold standard for stone burden; identifies tiny calcium‑oxalate crystals.
• Bone scan or MRI: Used when systemic oxalosis is suspected.

Differential diagnosis

Secondary hyperoxaluria (e.g., excessive dietary oxalate, intestinal malabsorption, vitamin C megadoses) must be excluded before confirming a primary form.

Treatment Options

Management combines **lifestyle measures**, **pharmacologic therapy**, and in severe cases, **organ transplantation**. Treatment is individualized according to disease type, stage, and patient age.

Hydration & dietary modifications

• Goal: > 2.5–3 L of fluid intake daily (or 30 mL/kg) to dilute urinary oxalate.
• Low‑oxalate diet: limit spinach, nuts, rhubarb, beets, chocolate, and tea.
• Avoid high‑dose vitamin C (> 1 g/day) because it metabolizes to oxalate.
• Calcium citrate (1–2 g/day) taken with meals to bind dietary oxalate in the gut.

Pharmacologic therapy

• Pyridoxine (Vitamin B6): Effective for many PH‑1 patients with specific AGXT mutations (e.g., p.Gly170Arg). Dose 5–20 mg/kg/day up to 500 mg/day.
Reference: Mayo Clinic
• Potassium citrate: Increases urinary citrate, which inhibits stone formation.
• Oxalate‑degrading probiotics (e.g., Oxalobacter formigenes): Still investigational; early trials show modest reduction in urinary oxalate.
• Liver‑targeted RNAi therapy (Lumasiran): FDA‑approved (2020) for PH‑1; silences glycolate oxidase, reducing hepatic oxalate production.
• Dialysis: Hemodialysis (≥ 6 h, 4–5 times/week) or peritoneal dialysis can temporarily lower plasma oxalate in ESRD, but does not stop production.

Surgical / procedural interventions

• Stone removal: Extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, or percutaneous nephrolithotomy (PCNL) as needed.
• Kidney transplant: Improves renal function but does **not** stop oxalate production; high recurrence risk if the liver defect persists.
• Combined liver‑kidney transplant: Considered the definitive cure for PH‑1, replacing the source of oxalate production (liver) and the damaged kidneys.

Emerging therapies

• Gene‑editing approaches (CRISPR‑Cas9) are in pre‑clinical stages.
• Small‑molecule chaperones that stabilize mutant AGT.

Living with Holliday‑Segar disease (Primary hyperoxaluria)

Effective self‑management can markedly slow disease progression and improve quality of life.

Daily hydration strategy

• Carry a water bottle; aim for a sip every 10–15 minutes.
• Flavor water with citrus (lemon or lime) – citrate helps inhibit stone formation.

Nutrition tips

• Follow a registered dietitian’s low‑oxalate plan; keep a food diary.
• Prefer low‑oxalate vegetables (cabbage, cauliflower, cucumbers) and fruit (apples, berries).
• Maintain adequate calcium (1,000–1,200 mg/day) – calcium binds oxalate in the gut.
• Limit sodium (< 2 g/day) to reduce calcium excretion.

Medication adherence

• Set alarms or use pill‑organizer boxes for pyridoxine and citrate.
• Report side‑effects (e.g., neuropathy from high‑dose B6) to your physician promptly.

Regular monitoring

• Every 3–6 months: serum creatinine/eGFR, plasma oxalate, and urine oxalate.
• Annual imaging (ultrasound) to assess stone burden.
• Genetic counseling for family planning.

Psychosocial support

• Connect with patient advocacy groups such as the Primary Hyperoxaluria Foundation.
• Consider counseling to address anxiety related to chronic kidney disease.

Prevention

Because PH is genetic, primary prevention (preventing the disease from occurring) is not possible. However, secondary prevention—reducing stone formation and slowing kidney damage—is achievable.

• Genetic screening for at‑risk couples (especially in high‑prevalence regions).
• Early testing of siblings of diagnosed patients.
• Strict adherence to hydration and low‑oxalate diet.
• Avoid medications that increase calcium excretion (e.g., loop diuretics) unless medically necessary.

Complications

If left untreated or poorly controlled, PH can lead to serious, sometimes life‑threatening complications.

• End‑stage renal disease (ESRD): Requires dialysis or transplant; occurs in ~70 % of PH‑1 patients by age 30.
• Systemic oxalosis: Deposition in heart, bone, retina, skin, and peripheral nerves.
• Cardiomyopathy: Oxalate infiltration may cause heart failure or arrhythmias.
• Loss of vision: Retinal crystal deposits can lead to visual field defects.
• Bone fractures and osteomalacia: Due to skeletal oxalate deposition.
• Recurrent urinary tract infections: From obstructive stones.

When to Seek Emergency Care

References

• Mayo Clinic. Primary Hyperoxaluria. https://www.mayoclinic.org
• Cleveland Clinic. Primary Hyperoxaluria – Diagnosis and Treatment. https://my.clevelandclinic.org
• National Institutes of Health (NIH) – Genetic and Rare Diseases Information Center. Primary Hyperoxaluria. https://rarediseases.info.nih.gov
• World Health Organization. Guidelines for the Management of Rare Metabolic Disorders. 2022.
• Gauguet, A. et al. Lumasiran for Primary Hyperoxaluria Type 1. *N Engl J Med.* 2020;383:252–262.
• Knauf, F., & Sienkiewicz, M. Nutrition Management in Primary Hyperoxaluria. *Kidney International.* 2021;99(3):563‑572.